AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

Christopher L. Bowlus; Lionel Arrivé; Annika Bergquist; Mark Deneau; Lisa Forman; Sumera I. Ilyas; Keri E. Lunsford; Mercedes Martinez; Gonzalo Sapisochin; Rachna Shroff; James H. Tabibian; David N. Assis

doi:10.1002/hep.32771

AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

Christopher L. Bowlus, Lionel Arrivé, Annika Bergquist, Mark Deneau, Lisa Forman, Sumera I. Ilyas, Keri E. Lunsford, Mercedes Martinez, Gonzalo Sapisochin, Rachna Shroff, James H. Tabibian, David N. Assis

Gastroenterology and Hepatology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	659-702
Number of pages	44
Journal	Hepatology
Volume	77
Issue number	2
DOIs	https://doi.org/10.1002/hep.32771
State	Published - Feb 2023

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.32771

Cite this

@article{717ee33e55114edfaa21c08f182cd074,

title = "AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma",

author = "Bowlus, {Christopher L.} and Lionel Arriv{\'e} and Annika Bergquist and Mark Deneau and Lisa Forman and Ilyas, {Sumera I.} and Lunsford, {Keri E.} and Mercedes Martinez and Gonzalo Sapisochin and Rachna Shroff and Tabibian, {James H.} and Assis, {David N.}",

note = "Funding Information: Dr. Bergquist advises Ipsen and received grants from Gilead. Dr. Bowlus received grants from Gilead, Bristol‐Myers Squibb, GlaxoSmithKline, Mirum, Genkyotex, Boston Scientific, Intercept, Target, Novartis, BiomX, CymaBay, Genfit, COUR and Pliant. Dr. Assis received grants from Gilead. Dr. Sapisochin consults and advises Integra. He consults and received grants from Roche. He consults for AstraZeneca, Novartis and Evidera. Dr. Forman received grants from Gilead, CymaBay and Mirum. Dr. Deneau consults for Gilead, HighTide and Mirum. Dr. Shroff advises and is on the speakers{\textquoteright} bureau for Servier. She advises and received grants from Merck and QED. She consults for SYROS. She advises AstraZeneca, Boehringer Ingelheim, Genentech, CAMI, Clovis, Incyte and Zymeworks. She received grants from Bayer, Bristol‐Myers Squibb, Exelixis, IMV, LOXO, Novocure, NUCANA, Pieris, Rafeal, Seagen and Taiho. Dr. Ilyas consults for AstraZeneca. Dr. Tabibian consults for Olympus. Funding Information: Funding for the development of this Practice Guidance was provided by the American Association for the Study of Liver Diseases. ",

year = "2023",

month = feb,

doi = "10.1002/hep.32771",

language = "English (US)",

volume = "77",

pages = "659--702",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "2",

}

TY - JOUR

T1 - AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

AU - Bowlus, Christopher L.

AU - Arrivé, Lionel

AU - Bergquist, Annika

AU - Deneau, Mark

AU - Forman, Lisa

AU - Ilyas, Sumera I.

AU - Lunsford, Keri E.

AU - Martinez, Mercedes

AU - Sapisochin, Gonzalo

AU - Shroff, Rachna

AU - Tabibian, James H.

AU - Assis, David N.

N1 - Funding Information: Dr. Bergquist advises Ipsen and received grants from Gilead. Dr. Bowlus received grants from Gilead, Bristol‐Myers Squibb, GlaxoSmithKline, Mirum, Genkyotex, Boston Scientific, Intercept, Target, Novartis, BiomX, CymaBay, Genfit, COUR and Pliant. Dr. Assis received grants from Gilead. Dr. Sapisochin consults and advises Integra. He consults and received grants from Roche. He consults for AstraZeneca, Novartis and Evidera. Dr. Forman received grants from Gilead, CymaBay and Mirum. Dr. Deneau consults for Gilead, HighTide and Mirum. Dr. Shroff advises and is on the speakers’ bureau for Servier. She advises and received grants from Merck and QED. She consults for SYROS. She advises AstraZeneca, Boehringer Ingelheim, Genentech, CAMI, Clovis, Incyte and Zymeworks. She received grants from Bayer, Bristol‐Myers Squibb, Exelixis, IMV, LOXO, Novocure, NUCANA, Pieris, Rafeal, Seagen and Taiho. Dr. Ilyas consults for AstraZeneca. Dr. Tabibian consults for Olympus. Funding Information: Funding for the development of this Practice Guidance was provided by the American Association for the Study of Liver Diseases.

PY - 2023/2

Y1 - 2023/2

UR - http://www.scopus.com/inward/record.url?scp=85140232889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140232889&partnerID=8YFLogxK

U2 - 10.1002/hep.32771

DO - 10.1002/hep.32771

M3 - Article

C2 - 36083140

AN - SCOPUS:85140232889

SN - 0270-9139

VL - 77

SP - 659

EP - 702

JO - Hepatology

JF - Hepatology

IS - 2

ER -

AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this